Search
Filter Results
Displaying 571–580 of 719 for “Visions 2020”
-
The Usher 1B Workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about Usher 1B disease pathology, disease models, clinical characteristics and therapeutic approaches.
-
Jul 19, 2021
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
While the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
Jun 22, 2021
This June 30th exclusive conversation and acoustic performance by Grammy-nominated rocker Grace Potter will raise awareness and funds to find treatments and cures for blinding diseases.
-
Jun 15, 2021
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Additional results from the trial will be reported at a future scientific meeting
-
May 5, 2021
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Gene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
Jan 26, 2021
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Company will seek marketing approval for the emerging therapy
-
Jan 13, 2021
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Company also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
Jan 7, 2021
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
In a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
A friendly year end reminder to make sure you are aware of a popular end-of-year giving opportunity. In 2020, organizations like the Foundation Fighting Blindness have seen a huge uptick in gifts made through appreciated stock/securities. This is a great way to avoid capital gains taxes AND support a mission that’s important to you.
-
Dec 10, 2020
Mr. Ginsberg brings twenty-five years of rare disease corporate development, finance, strategy, and investment leadership experience.